JPRN-jRCT2080225217已完成2 期
Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer - OLAPem
ational Cancer Center Hospital East0 个研究点目标入组 30 人开始时间: 2020年6月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •1.Has given signed informed consent to participate in the clinical trial of her own will.
- •2. Is aged 20 years or older on the day of signing the informed consent.
- •3. Has been diagnosed with histologically confirmed, Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer by the International Federation of Gynecology and Obstetrics (FIGO) staging system (2014), with a histological type of high-grade serous or Grade 3 endometrioid carcinoma.
- •4. Have measurable disease based on RECIST 1.1.
- •5. Is a candidate for debulking surgery.
- •6. Has an HRD-positive tumor.
- •7. Has an ECOG Performance Status of 0 or 1.
- •8. Laboratory test results within 21 days prior to enrollment have met the following organ function criteria. However, measurements within 14 days of blood transfusion or administration of granulocyte-colony stimulating factor (G-CSF) are excluded.
- •Neutrophil count >= 1,500/mm3
- •Platelet count >= 100,000/mm3
- •Hemoglobin >= 9.0 g/dL
- •Serum creatinine =< 1.5 x ULN, or creatinine clearance >= 50 mL/min
- •T-Bil =< 2.0 mg/dL
- •ALT and AST =< 100 U/L (=< 200 U/L if liver metastasis is present)
- •9. A woman of childbearing potential must agree to use contraception after signing the informed consent, throughout the study period, and until at least 120 days following the last dose of the study drug
排除标准
- •1. Has received previous allogeneic bone-marrow transplantation.
- •2. Has concurrent interstitial lung disease/pneumonitis, or a history of (noninfectious) interstitial lung disease/pneumonitis that required treatment with steroids. Interstitial lung disease/pneumonitis includes radiation pneumonitis.
- •3. Has received prior antitumor therapy (e.g., chemotherapy, molecular-targeted therapy, therapeutic antibody, endocrine therapy, immunotherapy, and investigational therapy).
- •4. Has received surgery under general anesthesia within 28 days prior to enrollment. However, surgery to diagnose ovarian/fallopian tube/peritoneal cancer performed under general anesthesia is allowed.
- •5. Has received radiation or radioactive isotope therapy within 28 days prior to enrollment.
- •6. Has uncontrolled pericardial effusion, pleural effusion, or peritoneal effusion.
- •7. Has a history of cerebral infarction, cerebral hemorrhage, or transient cerebral ischemia within 180 days prior to enrollment.
- •8. Has a history of deep vein thrombosis or pulmonary embolism.
- •9. Is receiving systemic glucocorticoid therapy or systemic immunosuppressive therapy.
- •10. Has a history of autoimmune disease.
- •11. Is infected with human immunodeficiency virus (HIV).
- •12. Is infected with active* hepatitis B or hepatitis C.
- •*: Active hepatitis B is defined as HBs antigen positive.
- •13. Has a symptomatic infection within 14 days prior to enrollment.
- •14. Has received a live vaccine within 28 days prior to enrollment.
- •15. Has clinically critical cardiac disease (has a history of myocardial infarction or angina pectoris within 180 days prior to enrollment or has New York Heart Association [NYHA] class II or higher cardiac failure, uncontrolled arrhythmia, or QTc prolongation defined as QTc > 470 msec).
- •16. Has active brain metastasis or a tumor causing spinal cord compression.
- •17. Is pregnant or breastfeeding.
- •18. Has a history of severe allergy, anaphylaxis, or hypersensitivity induced by humanized chimeric antibodies.
- •19. Is allergic to biologics produced from Chinese hamster ovary (CHO) cells, carboplatin, or paclitaxel.
- •20. Has a known or suspected active malignancy that is different from the disease of interest in the clinical trial or has a history of other malignancy within 3 years prior to enrollment. However, cutaneous basal cell carcinoma and cervical carcinoma in situ are not part of this exclusion criterion.
- •21. Is unwilling to or unable to comply with the protocol.
- •22. Is not eligible to enroll in the clinical trial based on the judgment by the Investigator or Sub-investigator.
研究者
相似试验
进行中（未招募）
1 期
Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancerasopharyngeal cancerMedDRA version: 21.0Level: LLTClassification code 10028793Term: Nasopharyngeal carcinomaSystem Organ Class: 100000004864EUCTR2020-004649-35-ITFondazione GONO30
进行中（未招募）
2 期
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Metastatic Triple Negative Breast CancerNCT03330847AstraZeneca273
已完成
2 期
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial CarcinosarcomaEndometrial CarcinosarcomaNCT05156268Memorial Sloan Kettering Cancer Center26
招募中
2 期
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) MutationMetastatic MelanomaNCT04633902California Pacific Medical Center Research Institute41
Unknown
2 期
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical CancerCervical CancerNCT04641728Saitama Medical University International Medical Center28